Hegseth’s Military Testosterone Plan Sparks Debate Over Masculinity and Medical Risks

Key points

• Hegseth’s July memo mandates annual testosterone screening for service members over 30, with voluntary replacement therapy for those with low levels.
• The FDA recently proposed removing warnings about heart attack and stroke risks for TRT, citing the TRAVERSE trial, though it noted increased risks for atrial fibrillation and blood clots.
• Medical experts, including Dr. Arthur Burnett of Johns Hopkins, emphasize that TRT should only treat confirmed clinical deficiency, not enhance performance or correct normal age-related declines.
• Fox News host Jesse Watters joked that increased testosterone could lead to sexual violence against women, a claim experts dismiss as biologically unfounded but socially harmful.
• A review of over one million men indicates average testosterone levels have dropped by 20% over the past half-century, though measurement methods vary.

Background

This policy follows a broader trend in the current administration, including FDA moves to expand TRT access and previous controversies over transgender service bans. In July 2026, a federal judge ordered the Pentagon to justify the testosterone policy, questioning its medical rationale and consistency with other gender-related military regulations. Earlier analysis from Slate criticized the plan as ill-informed, noting that modern warfare relies more on strategy and technology than hormonal boosts.

How outlets are covering it

USA Today highlights the social backlash, particularly the 'toxic masculinity' narrative and the fear that the policy frames sexual assault as a biological inevitability. The Atlantic focuses on the epidemiological trend of declining testosterone levels, noting a 20-50% drop over 50 years, but questions the necessity of mass screening. Harvard Health provides a clinical perspective, detailing the FDA’s regulatory shift based on the TRAVERSE trial, which found no elevated cardiovascular risk but noted other side effects like kidney injury. While USA Today and The Atlantic emphasize the social and cultural implications, Harvard Health focuses on the medical nuances of diagnosis and risk management, noting that TRT is appropriate for confirmed hypogonadism but requires careful monitoring for prostate and blood clot issues.

Why it matters

The policy intersects with public health, military readiness, and gender politics. It risks normalizing the use of hormones for performance enhancement rather than medical treatment, potentially leading to long-term health issues for service members. Furthermore, the public discourse surrounding the policy reinforces harmful stereotypes about masculinity and sexual violence, distracting from evidence-based approaches to mental health and physical fitness in the military.

What to watch

The FDA will finalize its proposed labeling changes for TRT, which could make the therapy more accessible. The Pentagon is expected to implement the screening program, though legal challenges may delay full rollout. Medical experts will continue to monitor the long-term effects of TRT on military personnel, particularly regarding cardiovascular and prostate health.